Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial (Q91733167)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

title

Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

main subject

phase III clinical trial

1 reference

multicenter clinical trial

inferred from title

1 reference

5

Hiroji Iwata

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

13

Suzette Delaloge

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

author name string

Robert Coleman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Dianne M Finkelstein

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Carlos Barrios

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Miguel Martin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Roberto Hegg

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

John Glaspy

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Alvaro Montaño Periañez

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Katia Tonkin

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Ines Deleu

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Joohyuk Sohn

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

John Crown

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Tian Dai

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Ying Zhou

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Danielle Jandial

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Arlene Chan

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

publication date

2 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

24 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

page(s)

60-72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics

24 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Bone metastases in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Identifying breast cancer patients at high risk for bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Competing risks regression for stratified data.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

The Osteoclast in Bone Metastasis: Player and Target

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Bone metastasis: pathogenesis and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Mechanisms of bone metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2819%2930687-4

7 January 2021

10.1016/S1470-2045(19)30687-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31806543%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

1 reference